{
    "info": {
        "nct_id": "NCT06369246",
        "official_title": "PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer",
        "inclusion_criteria": "1. Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate within one year of study entry. Evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson.\n\n   1. cT1c-T3a by digital exam or imaging (AJCC 8th Ed.). No cT3b-4 by digital exam or imaging (AJCC 8th Ed.)\n   2. Gleason Grade Group 2-5 (Gleason 7, 8, 9, 10).\n   3. If Gleason Grade 2, must meet definition of unfavorable intermediate risk (at least one of the following: cT2b, PSA >10 ng/mL prior to starting androgen deprivation therapy (ADT).\n\n   If a participant is taking 5-alpha reductase inhibitors the measured PSA may be doubled).\n2. Node negative by conventional imaging.\n3. Be ≥ 18 years of age on the day of signing informed consent.\n4. Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 185 days prior to registration; Please note: baseline PSA must be obtained prior to the start of any ADT.\n5. ECOG performance status 0-2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe RT.\n2. Prior prostatectomy, cryosurgery, or HIFU for adenocarcinoma of the prostate\n3. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields\n4. Distant metastatic disease on conventional imaging, which by the discretion of the treating physician cannot be treated definitively.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. ECOG performance status 0-2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Node negative by conventional imaging.",
            "criterions": [
                {
                    "exact_snippets": "Node negative by conventional imaging",
                    "criterion": "lymph node status by conventional imaging",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Gleason Grade Group 2-5 (Gleason 7, 8, 9, 10).",
            "criterions": [
                {
                    "exact_snippets": "Gleason Grade Group 2-5 (Gleason 7, 8, 9, 10)",
                    "criterion": "Gleason Grade Group",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "If a participant is taking 5-alpha reductase inhibitors the measured PSA may be doubled).",
            "criterions": [
                {
                    "exact_snippets": "participant is taking 5-alpha reductase inhibitors",
                    "criterion": "5-alpha reductase inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. If Gleason Grade 2, must meet definition of unfavorable intermediate risk (at least one of the following: cT2b, PSA >10 ng/mL prior to starting androgen deprivation therapy (ADT).",
            "criterions": [
                {
                    "exact_snippets": "Gleason Grade 2",
                    "criterion": "Gleason grade",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "2"
                        }
                    ]
                },
                {
                    "exact_snippets": "must meet definition of unfavorable intermediate risk (at least one of the following: cT2b, PSA >10 ng/mL prior to starting androgen deprivation therapy (ADT)",
                    "criterion": "unfavorable intermediate risk",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cT2b",
                    "criterion": "clinical tumor stage (cT)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "T2b"
                        }
                    ]
                },
                {
                    "exact_snippets": "PSA >10 ng/mL prior to starting androgen deprivation therapy (ADT)",
                    "criterion": "prostate-specific antigen (PSA) level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "ng/mL"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting androgen deprivation therapy (ADT)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate within one year of study entry. Evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate",
                    "criterion": "adenocarcinoma of prostate diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within one year of study entry",
                    "criterion": "time since diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "time_interval",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "histological confirmation takes place at MD Anderson",
                    "criterion": "histological confirmation at MD Anderson",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "MD Anderson"
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Be ≥ 18 years of age on the day of signing informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Be ≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "on the day of signing informed consent",
                    "criterion": "age at time of consent",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "on the day of signing informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 185 days prior to registration; Please note: baseline PSA must be obtained prior to the start of any ADT.",
            "criterions": [
                {
                    "exact_snippets": "Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 185 days prior to registration",
                    "criterion": "onset of androgen ablation",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 185,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "baseline PSA must be obtained prior to the start of any ADT",
                    "criterion": "baseline PSA",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to ADT start",
                            "expected_value": "obtained prior to the start of any ADT"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. cT1c-T3a by digital exam or imaging (AJCC 8th Ed.). No cT3b-4 by digital exam or imaging (AJCC 8th Ed.)",
            "criterions": [
                {
                    "exact_snippets": "cT1c-T3a by digital exam or imaging (AJCC 8th Ed.)",
                    "criterion": "clinical tumor stage (cT)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "T1c"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "T3a"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "No cT3b-4 by digital exam or imaging (AJCC 8th Ed.)",
                    "criterion": "clinical tumor stage (cT)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "T3b"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "3. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields",
            "criterions": [
                {
                    "exact_snippets": "Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields",
                    "criterion": "prior radiotherapy to the region of the study cancer",
                    "requirements": [
                        {
                            "requirement_type": "overlap of radiation fields",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Distant metastatic disease on conventional imaging, which by the discretion of the treating physician cannot be treated definitively.",
            "criterions": [
                {
                    "exact_snippets": "Distant metastatic disease on conventional imaging",
                    "criterion": "distant metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "conventional imaging"
                        }
                    ]
                },
                {
                    "exact_snippets": "which by the discretion of the treating physician cannot be treated definitively",
                    "criterion": "treatability of distant metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "treatability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "assessment_by",
                            "expected_value": "discretion of the treating physician"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe RT.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of active scleroderma",
                    "criterion": "scleroderma",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... lupus",
                    "criterion": "lupus",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... other rheumatologic disease",
                    "criterion": "other rheumatologic disease",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "2. Prior prostatectomy, cryosurgery, or HIFU for adenocarcinoma of the prostate",
            "criterions": [
                {
                    "exact_snippets": "Prior prostatectomy ... for adenocarcinoma of the prostate",
                    "criterion": "prostatectomy for adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior cryosurgery ... for adenocarcinoma of the prostate",
                    "criterion": "cryosurgery for adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior ... HIFU for adenocarcinoma of the prostate",
                    "criterion": "HIFU for adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}